Unknown EARLY_PHASE1 INTERVENTIONAL 1-arm NCT01772303

Safety and Efficacy Study of HO/03/03 10-40 Micro Grams to Treat Hard to Heal Wounds (H2H)

An Open-Label, Prospective, Multicenter Study to Assess the Safety and Efficacy of HO/03/03 10-40 Micro Gram (Wound Size Dependence) Applied Topically for up to 24 Weeks in Subjects With Various Etiologies of Hard-to-Heal Wounds

Sponsor: HealOr

Conditions Hard to Heal Wounds

Interventions HO/03/03 10-40 µg

Updated 6 times since 2017 Last updated: Apr 3, 2013 Started: Jan 31, 2013 Primary completion: Aug 31, 2013 Completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01772303, this EARLY_PHASE1 trial focuses on Hard to Heal Wounds and remains ongoing. Sponsored by HealOr, it has been updated 6 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown EARLY_PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status EARLY_PHASE1
Jun 2018 — Jan 2021 [monthly]

Unknown Status EARLY_PHASE1
Feb 2017 — Jun 2018 [monthly]

Unknown Status EARLY_PHASE1

Phase: Phase 0 → EARLY_PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Unknown Status Phase 0

First recorded

Jan 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

HealOr

Data source: HealOr

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Haifa, Israel